AstraZeneca PLC
http://www.astrazeneca.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AstraZeneca PLC
Humira Biosimilars Prepare For US Competition In 2023
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.
Big Pharma Restructures Commercial Teams In India
More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.
AAM CEO Leonard Departs After Two Years, Creating Another Trade Group Searching For New Leader
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.
Perrigo Supports Hypoallergenic Infant Formula Savings Claims, Not Equivalence To Enfamil Brand
Perrigo can continue claiming its store brand hypoallergenic infant formula saves customers more than 20% compared to leading name brands while providing similar nutrition to leading brands. But meeting AAP standard doesn’t measure up as equivalent to brands, industry self-regulation group says.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alexion Pharmaceuticals Inc.
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Aviron
- Cellective Therapeutics, Inc.
- Definiens
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Medimmune
- Novexel
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma